Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Shares gained 9.6% through November 19; Q3 earnings and revenue beat consensus, JORNAY PM sales grew 24%, and the company completed a $50 million share repurchase.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Compression ⢠Rising Leverage ⢠Positive Cash Flow COLL's strong FY2025 profitability has deteriorated sharply into a quarterly loss with weaker margins, strained liquidity, and higher leverage, despite positive operating cash flow.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Three-day rebound ⢠Key support Support Level: $21.84 Resistance Level: $23.36â$23.70 COLL remains in a bearish last-month trend despite a tentative three-day rebound; hold above $21.84, but a move through $23.36â$23.70 is needed to confirm stabilization.
Sentiment & News
Key News Insights: ⢠BlackRock stake ⢠Price decline ⢠Investor engagement ⢠News View: Large institutional positions may support sentiment, but near-term share performance remains volatile. Collegium shares weakened despite major new institutional buying and ongoing investor outreach, signaling improved long-term interest amid near-term pressure.
AI Summary
COLL is a leveraged ADHD-platform transitionânot a simple value playâwhere JORNAY PM and AZSTARYS growth can unlock significant upside only if margin recovery and free-cash-flow-driven deleveraging materially improve interest coverage; investors should prioritize quarterly EBITDA, cash conversion, and net-debt reduction over buybacks.
Description
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company that develops and markets prescription treatments for pain management. Its offerings include an abuse-deterrent extended-release oxycodone formulation and both immediate- and extended-release tapentadol products intended for severe, long-term, around-the-clock pain control. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 20 | Nov 27 | COLL | Collegium Pharmaceutical, Inc. | Shares gained 9.6% through November 19; Q3 earnings and revenue beat consensus, JORNAY PM sales grew 24%, and the company completed a $50 million share repurchase. | Active | +0.0% |